Related by context. All words. (Click for frequent words.) 76 XL# XL# 75 XL# XL# XL# XL# 75 XL# anticancer compounds 72 PDX pralatrexate 71 FOLOTYN ® 71 Daclizumab 71 alvespimycin 70 randomized discontinuation trial 69 Entereg R 69 orally administered inhibitor 69 AAG geldanamycin analog 69 Solazed TM 68 oral proteasome inhibitor 68 Panzem R NCD 68 ularitide 68 XL# [003] 68 TRIOLEX ™ 68 docetaxel Taxotere R 68 Azedra ™ 68 BRIM2 68 unique alkylating agent 68 relapsed refractory multiple myeloma 68 elotuzumab 68 virus HCV protease inhibitor 68 evaluating tivozanib 68 Exelixis compounds 68 Novel Oral 67 MKC# MKC# PP 67 novel VDA molecule 67 PNP inhibitor 67 investigational humanized monoclonal antibody 67 multicenter Phase III 67 adecatumumab MT# 67 oral prodrug 67 pan HDAC inhibitor 67 VEGFR2 inhibitor 67 phase IIb clinical 67 Glufosfamide 67 Phase #b/#a clinical 67 CYT# potent vascular disrupting 67 CD# CEA 67 MAGE A3 ASCI 67 Phase Ib II 67 metaglidasen 67 hypoxia activated prodrug 67 AKT inhibitor 67 Panzem R 66 HGS ETR2 66 Phase Ib clinical 66 JAK inhibitor 66 targeted radiotherapeutic 66 R roscovitine 66 ALN TTR 66 ENMD # 66 RGB # 66 mGluR5 negative 66 AEG# 66 receptor tyrosine kinase inhibitor 66 HGS ETR1 mapatumumab 66 mertansine 66 Cloretazine ® 66 OXi# 66 Presents Preclinical Data 66 Zemiva ™ 66 EGFR HER2 66 TASKi2 66 specific CCR9 antagonist 66 Zoraxel TM 66 candidate AQ4N 66 Phase 1b clinical trials 66 liposomal formulation 66 Phase Ib clinical trials 66 Sapacitabine 66 ALN HPN 66 R sorafenib tablets 66 FOLFOX6 chemotherapy regimen 66 HCV protease inhibitor 66 investigational pan BCR 66 Aflibercept 66 lintuzumab SGN 66 multi kinase inhibitor 66 PI3K/Akt pathway inhibitor 66 phase IIa clinical 66 non nucleoside inhibitor 66 Panzem NCD 66 Archexin 65 Aurexis 65 ganetespib 65 Kinase Inhibitor 65 dependent kinase inhibitor 65 huC# DM4 65 selective androgen receptor modulator 65 Telik logo TELINTRA 65 dextromethorphan quinidine 65 ongoing Phase 1b 65 Meets Primary Endpoint 65 selective immunoproteasome inhibitor 65 triciribine phosphate monohydrate 65 Completes Patient Enrollment 65 HCD# [002] 65 Azedra TM 65 HGS ETR1 65 CR# vcMMAE 65 Initiates Phase II 65 HGS# 65 sapacitabine CYC# 65 selective kinase inhibitor 65 enzastaurin 65 MT# MEDI 65 telomerase inhibitor drug 65 Hsp# Inhibitor 65 Tezampanel 65 CD# monoclonal antibody 65 including eniluracil ADH 65 CCX# 65 Synavive ™ 65 RH1 65 novel anticancer 65 candidate CRLX# 65 Albuferon TM 65 randomized controlled multicenter 65 LymphoStat B belimumab 65 CEQ# 65 tanespimycin 65 oral nucleoside analogue 65 ABL inhibitor 65 Trofex ™ 65 Kosan dependence 65 PKC# 65 Phase IIa trials 65 tiapamil 65 PRT# 65 TELCYTA 65 product platforms AZX# 65 pertuzumab 65 APOPTONE 65 MKC# MT 65 CA4P 65 PXD# 65 Phase 2b clinical trials 65 Cloretazine R 65 PEG SN# 65 non nucleoside HCV 65 fosbretabulin 65 volociximab 65 TBC# 65 PS# [001] 65 PEG Interferon lambda 65 leading oral taxane 65 MCSP respectively 65 APEX PD 65 refractory chronic lymphocytic 65 Phase 1b trial 65 R#/MEM # 65 Xanafide 64 dasatinib Sprycel ® 64 Ceflatonin R 64 orally bioavailable 64 Phase 2b Clinical Trial 64 IAP inhibitors 64 TELINTRA 64 Initiated Phase 64 essential thrombocythemia ET 64 bardoxolone 64 trastuzumab Herceptin R 64 PSN# [002] 64 developing Bicifadine serotonin 64 rxRNA 64 ALN PCS 64 Aurora kinase inhibitor 64 Randomized Phase 64 seliciclib CYC# 64 HDAC Inhibitor 64 MEK inhibitor 64 Hedgehog Pathway Inhibitor 64 omecamtiv mecarbil formerly 64 Voreloxin 64 Zemiva TM 64 PrevOnco 64 IMiDs R 64 bevacizumab Avastin ® 64 oral picoplatin 64 MGCD# [002] 64 Personalized Immunotherapy 64 PDE4 inhibitor 64 TRANSDUR ® 64 Fovea Pharmaceuticals subsidiary 64 EDEMA3 64 dacetuzumab SGN 64 Serdaxin ® 64 novel topoisomerase 64 Phase Ib IIa 64 Amrubicin 64 includes TOLAMBA TM 64 generation proteasome inhibitor 64 Phase Ib study 64 Phase 2a clinical 64 TAFA# 64 Annamycin 64 IMA# 64 sunitinib malate 64 IgG1 monoclonal antibody 64 EOquin TM 64 Pimavanserin 64 mapatumumab 64 Elagolix 64 ocular formulation 64 Pivotal Phase 64 SAR# [004] 64 ThermoDox ® clinical 64 small molecule chemotherapeutic 64 Guanilib 64 Oral NKTR 64 ARIKACE ™ 64 CTA# Injection 64 metastatic HRPC 64 systemic anaplastic large 64 Epratuzumab 64 AzaSite Plus 64 Combination REOLYSIN R 64 REG1 Anticoagulation System 64 Medidur TM FA 64 trastuzumab DM1 T DM1 64 THR beta agonist 64 pralatrexate injection folate analogue 64 MEK inhibitors 64 Factor VIIa 64 sodium thiosulfate STS 64 Crofelemer budesonide foam 64 Romidepsin 64 class mGluR5 inhibitor 64 LymphoStat B TM 64 sorafenib tablets 64 rNAPc2 64 P#X# antagonist 64 Phase Ib 64 JAK2 Inhibitor 64 transthyretin mediated amyloidosis ATTR 64 novel synthetic PEGylated 64 Budesonide MMX 64 FUSILEV ® 64 ENDEAVOR IV 64 compound ITMN 64 Curaxin CBLC# 64 histone deacetylase HDAC inhibitor 64 alpha folate receptor 64 TRANSDUR ™ 64 polycythemia vera PV 64 Carfilzomib 64 DDP# 64 OMP #R# 64 IAP inhibitor 64 Safinamide 64 SAR# [002] 64 PSMA ADC 64 Phase 2b clinical 64 Initiates Enrollment 63 IL# PE#QQR 63 GATTEX ™ 63 Nanobody 63 severe hypercholesterolemia 63 oral isoform selective HDAC 63 neratinib 63 Seliciclib 63 Anticalin R 63 BENLYSTA ® 63 Phase III Pivotal 63 JAK1 63 entinostat 63 Afatinib 63 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 63 UPLYSO 63 Randomized Double blind 63 nilotinib Tasigna ® 63 isoform selective 63 proteasome inhibitor 63 LX# LX# 63 Tesetaxel 63 cetuximab Erbitux R 63 2 inhibitor CYT# 63 R roscovitine CDK cyclin 63 Aurora kinase 63 phase III isavuconazole 63 Ostarine ™ 63 radiation sensitizer 63 IMPDH inhibitor 63 Bicifadine 63 Elotuzumab 63 Aplidin R 63 myelofibrosis polycythemia vera 63 Tyrima 63 evaluating satraplatin 63 ospemifene 63 HSP# inhibitor 63 either acutely decompensated 63 novel histone deacetylase 63 catheter occlusion 63 Initiate Phase 63 SinuNase ™ 63 Pivotal Phase III 63 EXPLORE Xa 63 pralatrexate 63 targeted kinase inhibitor 63 Solazed ™ 63 initiated Phase 1b 63 clinical trials Archexin ® 63 KRN# 63 Exherin 63 Azedra 63 castrate resistant prostate cancer 63 Apaziquone 63 Phase 2a Clinical Trial 63 Pafuramidine 63 CYC# 63 PROVENGE ® 63 Bezielle 63 myeloproliferative disorders 63 Traficet EN 63 GEM OS2 63 Saxagliptin 63 OvaRex R 63 Vicriviroc 63 small molecule glucokinase 63 rusalatide acetate 63 Ridaforolimus 63 Enzastaurin 63 SARMs 63 INCB# [001] 63 INCB# [002] 63 sNDA submission 63 systemically administered 63 oncolytic virus therapies 63 adecatumumab 63 recurrent NSCLC 63 selective androgen receptor modulators 63 R#/MEM 63 ON #.Na 63 TRC# 63 occlusion PAO 63 bevacizumab Avastin R 63 developing ostarine selective 63 registrational Phase 63 topically applied SEPA 63 reslizumab 63 Gemzar ® 63 PEGylated Fab fragment 63 LE SN# 63 drug pipeline TAFA# 63 Phase IIb Clinical Trial 63 Neo Urinary Conduit 63 refractory multiple myeloma 63 deforolimus 63 erlotinib Tarceva ® 63 Exelixis XL# 63 Alocrest 63 Tanespimycin 63 zanolimumab 63 ZYBRESTAT fosbretabulin 63 cMET 63 polymerase inhibitor 63 Deforolimus 63 Atiprimod 63 Commences Phase 63 generation purine nucleoside 63 Injectable Bone Graft 63 familial amyloidotic polyneuropathy FAP 63 PLK1 SNALP 63 NGX# 63 CDK inhibitor 63 MGCD# [001] 63 initiate Phase 1b 63 pan histone deacetylase 63 NOX E# 63 Chemophase 63 MT#/MEDI-# 63 agonistic human 63 generation Hsp# inhibitor 63 nitric oxide donating prostaglandin 63 GATTEX ® 63 lexidronam injection 63 recurrent metastatic ovarian cancer 63 CTAP# Capsules 63 Phase IIb Trial 63 XP# XP# 63 HuLuc# 63 Sym# 63 ATL# [002] 63 IMC #B 63 ulimorelin 63 TRAIL receptor antibodies 63 Phase 1b 63 docetaxel Taxotere ® 63 KRYSTEXXA TM pegloticase 63 selective modulator 63 humanized anti 63 CD4 monoclonal antibody 63 telomerase therapeutic 63 HepeX B TM 63 Aurora Kinase 63 Ophena TM 63 TMC# [002] 62 JAK2 inhibitor 62 TKB# 62 2 methoxyestradiol 62 Investigational Oral 62 blinded randomized placebo controlled 62 Asentar TM 62 vernakalant oral 62 molecular imaging radiopharmaceutical 62 mitogen activated ERK kinase 62 Pralatrexate 62 Phase III confirmatory 62 oral dihydropyrimidine dehydrogenase DPD 62 multicenter Phase II 62 developing ACAPODENE 62 AQ4N 62 Vidaza ® 62 CB2 selective receptor agonist 62 mocetinostat MGCD# 62 TLK# 62 palifosfamide Zymafos TM 62 Vascular Disrupting Agent 62 IMiDs 62 velafermin 62 HCV polymerase 62 TOCOSOL Paclitaxel 62 GW# [003] 62 controlled multicenter Phase 62 induced macular edema 62 ANYARA 62 NS5b 62 davunetide intranasal AL 62 acyclovir Lauriad R 62 sorafenib Nexavar 62 Augment TM 62 LEP ETU 62 Proxinium TM 62 Zemiva TM Trofex TM 62 investigational immunotherapy 62 anticancer compound 62 axitinib 62 Dalbavancin 62 Nasulin TM 62 phase IIb 62 albiglutide 62 forodesine 62 EGFr expressing metastatic colorectal 62 Perifosine 62 Epothilone D 62 initiated Phase Ib 62 ZFP Therapeutics 62 5 HT6 62 tezampanel 62 Ambrisentan 62 rALLy 62 opioid induced bowel dysfunction 62 intravesical infusion therapy 62 modified glutathione analog 62 OncoVEX GM CSF 62 YONDELIS 62 DURECT proprietary 62 RNAi Therapeutic 62 vapreotide acetate 62 delivers fluocinolone acetonide FA 62 huN# DM1 62 CCX# B 62 gastrointestinal disorders ATI 62 RenaZorb TM 62 Zenvia ™ 62 Mipomersen 62 highly selective endothelin 62 PDE# inhibitors 62 SCH # 62 Initiates Clinical 62 PF # [001] 62 Phase IIb III 62 EZN 62 next generation URAT1 62 catheter occlusion CO 62 sodium glucose cotransporter 62 hypoxia selective 62 GV# [001] 62 INSPIRE Trial Phase III 62 ISIS # 62 Azedra TM Onalta TM 62 ELND-#/AZD-# 62 SUTENT ® 62 Locteron ® 62 PHX# 62 pharmacogenomic translational research 62 Presents Preclinical 62 Antibody Drug Conjugate 62 dose escalation Phase 62 small molecule Hedgehog 62 peripherally acting 62 Ecallantide 62 BCX# 62 Golimumab 62 drug conjugate 62 Files Investigational 62 ALN VSP 62 romidepsin 62 LUMINATE 62 selective estrogen receptor modulator 62 MAP# 62 NEBIDO R 62 candidates Azedra TM 62 Myocet 62 confirmatory Phase III 62 BAY #-# 62 nab paclitaxel 62 Xeloda ® 62 allosteric modulator NAM 62 Apoptone 62 XYOTAX TM 62 gefitinib Iressa 62 BRIM3 62 diabetes irritable bowel 62 beta 1a 62 MKC# 62 SNALP technology 62 Plicera 62 Cetrorelix 62 Ovitrelle R Serostim 62 acetonide FA 62 Phase 1a clinical 62 Initiates Phase III 62 Entereg TM 62 investigational oral inhibitor 62 IIIa inhibitor 62 telaprevir VX 62 TACI Ig 62 celgosivir 62 PEG PAL 62 TELINTRA R 62 Trofex 62 Alfacell proprietary ribonuclease 62 tramiprosate Alzhemed TM 62 CD3 monoclonal antibody 62 UVIDEM 62 Cardium Therapeutics TM 62 interferon gamma 1b 62 evaluating carfilzomib 62 DUROS 62 Stedivaze 62 R lenalidomide 62 multicenter Phase 62 MYDICAR ® 62 cardiac myosin activator omecamtiv 62 Rebif ® 62 DB# [003] 62 randomized controlled Phase 62 Triolex 62 Cloretazine 62 antiangiogenic activity 62 TO AVOID PREGNANCY WHILE 62 GVAX ® 62 talactoferrin 62 delta opioid receptor 62 Hematide ™ 62 ADP receptor antagonist 62 DAVANAT 62 NVA# 62 Phase IIa clinical 62 ILUVIEN ® 62 erlotinib Tarceva R 62 Hedgehog pathway inhibitor 62 Iluvien ® 61 ATL# [001] 61 Trofex TM 61 adenosine injection 61 phase Ib clinical 61 investigational protease inhibitor 61 Presents Positive 61 registrational trial 61 Omacetaxine 61 Receives Orphan Drug 61 oral kinase inhibitor 61 urocortin 2 61 signal detection CTSD 61 Pharma Merck Serono 61 Angiocept 61 Xcytrin R 61 Vicinium TM 61 MEND CABG 61 metastatic castration resistant 61 CORT # 61 phase Ib 61 Dacogen injection 61 class anticancer quinolone 61 Trastuzumab DM1 61 oral Janus kinase 61 placebo controlled Phase III 61 Successfully Completes Phase 61 KSP inhibitor 61 IMiDs ® compound 61 IMC A# 61 Plecanatide 61 refractory NSCLC 61 lumiliximab 61 MIVI III 61 Pharmacokinetics PK 61 BR.# 61 PF # [002] 61 aldehyde dehydrogenase ALDH2 deficiency 61 CBLC# 61 MEK Inhibitor 61 AKIP ™ 61 potent topoisomerase II 61 PRTX 61 First Patient Dosed 61 candidates Augment ™ 61 Phase IIIb 61 oral gallium 61 oral ridaforolimus 61 dasatinib Sprycel 61 Initiates Phase 2b 61 L Annamycin 61 LHRH antagonists 61 pharmacokinetic PK 61 PEG PAL PEGylated recombinant 61 LHRH receptor positive 61 Aplidin 61 Phase 2b Study 61 immunosuppressive compound 61 thymalfasin 61 TRIOLEX HE# APOPTONE HE# 61 Asentar 61 phenylalanine ammonia lyase 61 Locked Nucleic Acid LNA 61 evaluating picoplatin 61 #/#/# Cytokinetics Incorporated 61 oral ghrelin agonist 61 Lixivaptan 61 kidney urologic 61 Microplasmin 61 compound KOS 61 castration resistant prostate cancer 61 lymphoid malignancies 61 generation nucleoside analog 61 Genasense oblimersen sodium Injection 61 galiximab 61 GetGoal Phase III 61 RELOVAIR ™ 61 placebo controlled clinical 61 Onyx Pharmaceuticals Announces 61 Alfimeprase 61 gemcitabine Gemzar ® 61 Combo Stent 61 ZEVALIN ® 61 lintuzumab 61 Phase 2a 61 commercialize CorMedix drug 61 Triapine 61 OX1 61 generation URAT1 inhibitor 61 tubulin inhibitor 61 EndoTAG TM -1 61 oral Hsp# inhibitor 61 CDK cyclin dependent 61 Vitaxin 61 commercializing Loramyc ® 61 SILENOR 61 mTOR inhibitor 61 Initiate Clinical Trial 61 kinase inhibitor 61 EOquin TM phase 61 Phase 1b clinical 61 vosaroxin 61 tezampanel NGX# 61 MET inhibitor 61 taxane resistant 61 ONX 61 Zenvia Phase III 61 ruxolitinib 61 generation DACH Platinum 61 AEGR 61 cilengitide 61 oxymorphone ER 61 small molecule tyrosine 61 compound INCB# 61 sarcoma melanoma 61 systemic RNAi therapeutic 61 Pivotal Trial 61 dacetuzumab 61 PEGylated interferon beta 1a 61 Cloretazine R VNP#M 61 BrachySil 61 epothilone 61 HQK 61 6R BH4 61 bazedoxifene conjugated estrogens 61 AP# [003] 61 Soliris eculizumab 61 ® bortezomib 61 angioedema indications 61 postoperative ileus POI 61 Intervention Effectiveness 61 ALN TTR# 61 Quinamed 61 tumor xenograft models 61 Amigal 61 NU# direct 61 PORxin TM platforms 61 CYP#A# CYP#D# 61 targeting Inflammatory Bowel 61 IMiDs ® 61 Genasense ® oblimersen 61 Talabostat 61 EOquin 61 Epothilones 61 plasma kallikrein inhibitor 61 signal transduction inhibitor 61 anti amnesic 61 Phase III Clinical Trial 61 Amigal TM 61 docetaxel chemotherapy 61 PROTEGE 61 Shigamabs ® 61 Belinostat 61 ARC# [002] 61 Zorbtive TM 61 Study Evaluating 61 CRx 61 Vidofludimus 61 Phase III Trial 61 vaccine GRNVAC1 61 HCV protease 61 ADVANCE PD 61 Nektar proprietary 61 antiplatelet compound 61 amrubicin 61 Pruvel ™ 61 favorable pharmacokinetic profile 61 CIMZIA ™ 61 cortisol synthesis 61 highly selective inhibitor 61 YONDELIS R 61 AzaSite Xtra 61 Nuvelo Announces 61 Tarceva TM 61 Nexavar ® 61 Luteinizing Hormone Releasing Hormone 61 aplastic anemia AA 61 Teriflunomide 61 lesinurad 61 MTP inhibitor 61 Selective Electrochemical Tumor Ablation 61 Ostabolin C TM 61 imetelstat GRN#L 61 sunitinib Sutent ® 61 orally inhaled migraine 61 skeletal sarcomere activators 61 vesicular monoamine transporter 61 midstage clinical 61 REOLYSIN ® 61 Pharmos proprietary 61 GATTEX TM 61 sapacitabine 61 MEND CABG II 61 Kahalalide F 61 preclinical efficacy 61 vascular disrupting agent 61 Brentuximab Vedotin SGN 61 HER1 61 ALS #-# 61 #D#C# 61 Serdaxin 61 Oracea TM 61 EGFr humanized monoclonal antibody 61 refractory gout 61 ATL/TV# 61 vemurafenib 61 Methylnaltrexone 61 pan BCR ABL 61 Completes Enrollment 61 Nanobody R 61 investigational compounds 61 Exherin TM 61 OvaRex ® MAb 61 XmAb# 61 relapsed myeloma 61 Fx #A 61 Budesonide foam crofelemer 61 candidate deforolimus 61 Anticancer Compound 61 Phase IIIb clinical 61 Reports Preclinical Data 61 evaluating Xcytrin 61 Phase #/#a 61 Ozarelix 61 JOULFERON 61 S1P antibody 60 Harbor BioSciences 60 metastatic hormone refractory 60 oral Azacitidine 60 GALNS 60 phase IIb trial 60 AVOREN 60 belinostat 60 subcutaneous formulation 60 Ceflatonin 60 CCR9 antagonist 60 RAS MAPK pathway 60 painful diabetic neuropathy 60 vidofludimus 60 diarrhea predominant irritable 60 Files IND 60 EGS# 60 Phase #/#a trial 60 BRAF inhibitor 60 fallopian tube cancers 60 Solazed 60 HER2 positive metastatic breast 60 JAK inhibitors 60 Sulonex TM 60 delivery polymer matrix 60 Topline Results 60 KNS # 60 Survivin antagonist 60 HuMax TAC 60 Antiviral Activity 60 solid tumors ZYBRESTAT 60 apoptosis inducer 60 HCV NS5B polymerase 60 Pegloticase 60 Androxal TM 60 Ocrelizumab 60 overactive bladder VANTAS R 60 Phase IIb randomized 60 Targretin capsules 60 OctoPlus licensed 60 Janus kinase 60 humanized monoclonal antibody 60 aurora kinase 60 GRN#L 60 tafamidis 60 TMC# C# 60 candidate REP# 60 mg q#h 60 ELND# 60 eculizumab 60 registrational 60 CYT# vascular disrupting 60 investigational monoclonal antibody 60 Evoltra ® 60 NCCTG 60 R Saizen R 60 somatostatin analogue 60 Anturol TM 60 Bayer HealthCare Onyx Pharmaceuticals 60 prokinetic agent 60 HuMax EGFr 60 generation antisense 60 placebo controlled Phase 60 5 fluorouracil leucovorin 60 mecarbil 60 Locked Nucleic Acid 60 Resten NG 60 acetylgalactosamine 6 60 DIRECT Trial 60 Clinical Trial Results 60 MDV# 60 atacicept 60 dyskinesia PD LID 60 Onalta ™ 60 novel orally administered 60 Thiarabine 60 RANK Ligand inhibitor 60 COU AA 60 candidate XP# 60 Excellarate TM 60 pomalidomide 60 antisense drug 60 AACR NCI EORTC 60 CORLUX CORT # 60 Phase IIa Clinical Trial 60 individualized cellular immunotherapy 60 MyVax R 60 trial evaluating PRX# 60 Dose Ranging Study 60 Oral Fingolimod 60 Pharmion Corporation 60 severe gastroparesis 60 delivered RNAi therapeutic 60 r hGH 60 mGluR5 NAM 60 otelixizumab 60 LymphoStat B 60 Ixabepilone 60 selective phosphodiesterase 60 anti botulism antibody 60 Serostim ® 60 protein kinase inhibitor 60 Azixa 60 INC# 60 nucleoside analog 60 Initiates Phase 60 RG# [001] 60 peptidic compound 60 CONQUER OB 60 compound PMX # 60 DASISION 60 Phenoptin 60 cell lymphoma CTCL 60 4SC AG ISIN DE# 60 pharmacokinetics PK 60 cyclin dependent kinase CDK 60 Dose Escalation 60 Lenocta TM 60 dimebon latrepirdine 60 evaluating mipomersen 60 cutaneous T cell 60 ALGRX 60 posaconazole 60 ENDEAVOR III 60 sorafenib Nexavar ® 60 Veronate R 60 plus Copegus R 60 Empatic ™ 60 Cleviprex TM clevidipine 60 GLP1 INT TM 60 antibody MAb 60 Hsp# inhibition 60 ZYBRESTAT 60 Genasense ® 60 Initiates Clinical Trial 60 Imprime PGG 60 HCV polymerase inhibitors 60 capecitabine Xeloda R 60 Bucindolol 60 OncoVex 60 TRX1 60 cannabinor 60 VELCADE melphalan 60 Prednisporin 60 Selzentry Celsentri 60 NS5B polymerase 60 investigational hepatitis C 60 CCR5 mAb 60 markets HP Acthar 60 viral kinetic 60 5 FU leucovorin 60 Virulizin ® 60 irreversible inhibitor 60 Pivotal Phase II 60 Dapagliflozin 60 Onco TCS 60 bendamustine 60 vinorelbine tartrate 60 vascular disrupting agents 60 Uvidem 60 ZACTIMA 60 Parkinson disease levodopa induced 60 TRACON Pharmaceuticals 60 Neulasta R 60 oral NKTR 60 eritoran 60 forodesine hydrochloride 60 ARRY # 60 LUX Lung 60 nitric oxide donating 60 6 sulfatase 60 ® decitabine 60 MOZOBIL 60 Bosutinib 60 NP2 Enkephalin 60 Lymphoseek ® 60 FavId 60 cholesteryl ester transfer 60 TLR9 agonist 60 alemtuzumab MS 60 Pertuzumab 60 DOS# 60 topical antifungal product 60 treat male hypogonadism 60 candidate custirsen 60 Lenocta 60 Drug Candidate 60 neuronal nicotinic receptor NNR 60 PI3K inhibitor 60 immunotherapeutic agent 60 ponatinib 60 histone deacetylase inhibitor 60 Maximum Tolerated Dose MTD 60 clinical trials SGN 60 REVIVE Diabetes 60 fostamatinib 60 histone deacetylase HDAC 60 hepatology portfolio 60 ferumoxytol Injection 60 cancer indications bafetinib 60 Begins Dosing 60 PARTNER Trial 60 epothilones 60 Receives Orphan Drug Designation 60 Vilazodone 60 TASKi3 60 DPX Survivac